Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Intellia Therapeutics Inc (38I.DU)

Dusseldorf - Dusseldorf Delayed Price. Currency in EUR
37.86+2.87 (+8.20%)
At close: 09:00PM CET
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close34.99
Open34.98
Bid38.10 x N/A
Ask38.53 x N/A
Day's Range34.92 - 37.86
52 Week Range29.97 - 89.58
Volume60
Avg. Volume2
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateFeb 22, 2023 - Feb 27, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for 38I.DU

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • InvestorPlace

      3 Gene Editing Stocks to Buy Now OR You’ll Be Kicking Yourself Later

      To many investors, gene editing sounds like the plot of a science fiction movie. The concept of being able to edit our DNA to cure genetic diseases is quite unbelievable, and the upside of gene editing to treat rare diseases is impressive. However, many gene editing stocks are making waves, looking to advance toward eradicating cancer and other serious illnesses. But ever since 2012, gene editing has been a reality, at least in terms of having the technology needed to edit genes. Don’t get me wr

    • InvestorPlace

      3 Gene Editing Stocks With the Best Long-Term Potential

      Gene editing stocks present themselves as one of the more lucrative investments in the healthcare sector. Gene editing, a revolutionary take on the science of genetic engineering, has the potential to countless lives around the globe. By introducing genetic material into cells, scientists can correct genetic abnormalities in a way never seen before. With the potential for vast improvements, gene therapy and gene editing are promising modern biotechnology forms.InvestorPlace - Stock Market News,

    • Motley Fool

      Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

      Cathie Wood is beating the market again so far in 2023, and that leaves growth investors wondering if she can recapture her 2020 performance in a bottle. Ark puts out daily transaction reports, so we know what Wood is buying and selling. Tesla bears think they're winning with the stock down 65% since hitting all-time highs in late 2021.

    Advertisement
    Advertisement